[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,460,548
  • Shares Outstanding, K 153,084
  • Annual Sales, $ 616,290 K
  • Annual Income, $ 447,180 K
  • EBIT $ 150 M
  • EBITDA $ 147 M
  • 60-Month Beta 1.62
  • Price/Sales 11.47
  • Price/Cash Flow 16.48
  • Price/Book 12.12

Options Overview Details

View History
  • Implied Volatility 56.17% (-2.39%)
  • Historical Volatility 53.28%
  • IV Percentile 41%
  • IV Rank 36.74%
  • IV High 82.81% on 10/16/25
  • IV Low 40.70% on 01/21/26
  • Expected Move (DTE 16) 4.16 (8.36%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 1,752
  • Volume Avg (30-Day) 2,245
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 64,872
  • Open Int (30-Day) 65,086
  • Expected Range 45.53 to 53.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.37
  • Number of Estimates 4
  • High Estimate $0.50
  • Low Estimate $0.27
  • Prior Year $2.43
  • Growth Rate Est. (year over year) -84.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.37 +8.41%
on 08/04/26
59.30 -17.07%
on 07/09/26
-4.13 (-7.75%)
since 07/02/26
3-Month
36.25 +35.67%
on 05/06/26
59.30 -17.07%
on 07/09/26
+13.08 (+36.23%)
since 05/05/26
52-Week
25.28 +94.54%
on 08/11/25
59.30 -17.07%
on 07/09/26
+20.78 (+73.17%)
since 08/05/25

Most Recent Stories

More News
TG Therapeutics: Q2 Earnings Snapshot

TG Therapeutics: Q2 Earnings Snapshot

TGTX : 49.55 (+1.66%)
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to...

TGTX : 49.55 (+1.66%)
TG Therapeutics Approaches Its First Test of Whether Last Quarter's Miss Was Noise or Pattern

Barchart Research What to Expect from TGTX Earnings TGTX Generated July 31, 2026 Current Price $52.03 EPS Estimate $$0.41 Consensus Rating Moderate Buy Average Move 12.28% TG Therapeutics Approaches Its...

TGTX : 49.55 (+1.66%)
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the...

TGTX : 49.55 (+1.66%)
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

NEW YORK , July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX)...

TGTX : 49.55 (+1.66%)
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant...

TGTX : 49.55 (+1.66%)
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed...

TGTX : 49.55 (+1.66%)
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or...

TGTX : 49.55 (+1.66%)
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman...

TGTX : 49.55 (+1.66%)
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no...

TGTX : 49.55 (+1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 53.67
2nd Resistance Point 51.33
1st Resistance Point 50.03
Last Price 49.55
1st Support Level 46.40
2nd Support Level 44.07
3rd Support Level 42.77

See More

52-Week High 59.30
Last Price 49.55
Fibonacci 61.8% 46.30
Fibonacci 50% 42.29
Fibonacci 38.2% 38.28
52-Week Low 25.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.